Fludarabine
Bispecific Chimeric Antigen Receptor (CAR) T Cells
University Hospital, Basel, SwitzerlandSmall moleculePhase 1Active
CC
43/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 28/ 100
- Competitive Position
- 89/ 100
Competitive context
3 Active assets in the Bispecific Chimeric Antigen Receptor (CAR) T Cells cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Cyclophosphamide University Hospital, Basel, Switzerland | Phase 1 | CC |
Anti-Cd19/20-Car Vector-Transduced T Cells University Hospital, Basel, Switzerland | Phase 1 | CC |
Bendamustine University Hospital, Basel, Switzerland | Phase 1 | CC |
Same molecule, other indications
Fludarabine is also rated in:
acute myeloid leukemia with abnormal bone marrow eosinophils inv(16)(p13q22) or t(16;16)(p13;q22)Dormant
BBB
Indicative ·
76 / 100
View asset →Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →